Evolus expands beyond neuromodulator competition with a 15-year exclusive deal for the hydration-focused biostimulator, no upfront fees.
Evolus has licensed exclusive U.S. distribution rights to Profhilo from IBSA under a 15-year agreement with no upfront payments—a structure that signals confidence in market uptake and ties economics to commercial success. Profhilo is a hybrid HA biostimulator (not PLLA or CaHA) that combines high-concentration hyaluronic acid with amino acids to drive skin quality and hydration rather than volume restoration.
This move diversifies Evolus beyond Jeuveau (prabotulinumtoxinA) and positions the company to capture medspa demand for skin-quality treatments that complement or compete with traditional filler protocols. Profhilo's mechanism—collagen and elastin stimulation via HA—appeals to practices seeking non-volumetric alternatives and differentiates from Galderma's Radiesse (CaHA) or AbbVie's Juvéderm Ultra (HA filler).
No upfront fees and a 15-year term signal Evolus is betting on Profhilo to compete in the skin-quality segment.
For practices, this adds another player to the injectables landscape. Evolus Rewards loyalty economics and Jeuveau pricing will likely shape how aggressively Profhilo is positioned against established filler portfolios.
Source: original report ↗
Frequently asked questions
What is Profhilo and how does it differ from traditional dermal fillers?
Profhilo is a hybrid hyaluronic acid biostimulator that combines high-concentration HA with amino acids to stimulate collagen and elastin production, focusing on skin quality and hydration rather than volume restoration. Unlike volumetric fillers like Juvéderm Ultra or Radiesse, Profhilo works through bio-stimulation rather than adding bulk, making it a non-volumetric alternative for skin quality treatments.
Who is distributing Profhilo in the United States?
Evolus secured exclusive U.S. distribution rights to Profhilo from IBSA under a 15-year agreement. Evolus, the maker of Jeuveau (prabotulinumtoxinA), now offers both neuromodulator and biostimulator options to practices.
How does Profhilo complement or compete with existing injectables?
Profhilo appeals to practices seeking skin-quality treatments that can complement traditional filler protocols or serve as a non-volumetric alternative. It differentiates from calcium hydroxyapatite options like Radiesse and traditional HA fillers, giving practices another tool to address hydration and collagen stimulation without volume addition.
What was the deal structure between Evolus and IBSA for Profhilo?
Evolus licensed exclusive U.S. distribution rights under a 15-year agreement with no upfront payments, meaning economics are tied to commercial success. This structure signals confidence in market uptake and aligns incentives between the licensor and distributor.
What mechanism does Profhilo use to improve skin quality?
Profhilo uses high-concentration hyaluronic acid combined with amino acids to stimulate collagen and elastin production, driving skin hydration and quality improvement. This bio-stimulation mechanism differentiates it from volumetric fillers that rely on direct tissue augmentation.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
